Protara Therapeutics, Inc. is a New York-based biopharmaceutical company focused on developing transformative therapies for patients with serious diseases. Its pipeline includes investigational treatments addressing cancer, lymphatic malformations, and nutritional needs associated with parenteral support.

The company’s lead candidate, TARA-002, is an investigational cell therapy based on OK-432, a broad immunopotentiator approved in Japan and Taiwan for several oncologic indications and lymphatic malformations. Protara is evaluating TARA-002 in the United States for non-muscle invasive bladder cancer and lymphatic malformations. For the latter, it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration.

Protara is also developing IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral support. The company reports that about 80% of these patients are choline deficient and have some degree of liver damage. IV Choline Chloride could potentially become the first FDA-approved intravenous choline formulation for this patient group. Protara shares information about its pipeline, clinical trials, publications, and career opportunities.